Naturecell's stock price soared to the daily price limit after the company won the first-instance ruling in a lawsuit to cancel the rejection of its product license approval for 'JointStem.'

According to the Korea Exchange on the 9th, Naturecell's stock price closed at the upper limit, finishing trading at 28,250 won, up 6,500 won (29.89%) from the previous trading day.

Earlier, Naturecell announced through a disclosure after the market close that the Seoul Administrative Court had ruled in favor of the plaintiff in a lawsuit seeking to cancel the rejection of the JointStem product license approval. The lawsuit was filed by RNL Regenerative Medicine Research Institute (formerly AL Bio), the developer of JointStem, against the Ministry of Food and Drug Safety to cancel the rejection of its application for manufacturing and sales product license approval for a pharmaceutical product. The Seoul Administrative Court issued the ruling in favor of the plaintiff on the 9th.

Regarding the background, the company stated that after the domestic product license for JointStem was rejected in August 2025, it had decided to maintain its domestic sales agreement until the results of the administrative lawsuit were finalized on August 19 of the same year. Additionally, through this disclosure, the company explained that the lawsuit was filed in September 2025 and that this ruling is based on the first-instance results from the Seoul Administrative Court.

However, since this ruling is a first-instance outcome, there is a possibility of additional changes to the product license approval process depending on whether an appeal is filed and the final ruling.

[This article was written with the assistance of AI, and the content is based on publicly available materials and market information. Some information may change over time, so please be sure to verify official sources such as Korea Exchange disclosures and corporate filings before making investment decisions. This article is not intended to recommend the purchase or sale of any specific stock or to solicit investment, and the final judgment and responsibility for investments lie with the reader.]